© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
November 09, 2021
"Certainly, the Optilume drug-coated balloon appears to be safe and effective in roughly two-thirds of patients at 3 years," said Justin Chee, MD.
October 14, 2021
“Optilume exhibited a significant improvement in [the primary] objective outcome at 6 months and subjective outcomes at 1-year post treatment compared to standard of care,” said Justin Chee, MBBS, FRACS.
August 12, 2021
In the pivotal phase 3 DAPA-CKD trial, dapagliflozin reduced the relative risk of worsening of renal function, onset of end-stage kidney disease, or cardiovascular or renal death by 39%.
August 11, 2021
The FDA’s decision not to approve roxadustat follows a vote from the agency’s Cardiovascular and Renal Drugs Advisory Committee that the drug’s benefit-risk profile does not support approval.
July 30, 2021
The FDA has issued a complete response letter regarding a new drug application for tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.
June 25, 2021
The mechanism of action of roxadustat differs from that of erythropoietin stimulating agents.
May 04, 2021
Lumasiran is the first drug approved by the FDA for the treatment of patients with primary hyperoxaluria type 1.
April 28, 2021
The application for the targeted release formulation of budesonide is supported by data from the phase 3 NefIgArd trial and the phase 2 NEFIGAN trial.
March 09, 2021
The retrospective study compared reintervention rates in the 4 standard surgical interventions for lower urinary tract symptoms due to benign prostatic obstruction.
January 18, 2021
Minimally-invasive treatment with the iTind device (Medi-Tate) provides rapid and sustained improvement of LUTS in men with BPH, without adversely affecting patients’ sexual function, according to a recently published 12-month study.